Aspen Pharmacare (OTCMKTS:APNHY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. “
APNHY stock traded up $0.05 during mid-day trading on Tuesday, hitting $21.65. The company had a trading volume of 9,753 shares, compared to its average volume of 37,448. The firm has a market cap of $9,642.54, a price-to-earnings ratio of 196.80, a P/E/G ratio of 1.27 and a beta of 0.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.56 and a current ratio of 0.89. Aspen Pharmacare has a 12 month low of $19.45 and a 12 month high of $24.60.
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies branded, OTC, and generic pharmaceutical products, infant nutritionals, and consumer healthcare products. The company offers various branded products for a range of therapeutic categories, including anaesthetics, analgesics, anti-retrovirals, blood and haemopoetic, cardio vascular system, central nervous system, endocrine system, gastro-intestinal tract, infant milk formulations, musculo-skeletal agents, NSAids, oncology, oral hygiene, respiratory system, and urinary tract system, as well as ear, nose, and throat.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aspen Pharmacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacare and related companies with MarketBeat.com's FREE daily email newsletter.